DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today that its third quarter 2025 financial results will be released before the market opens on November 5, 2025. MannKind will host a webcast beginning at 9 a.m. Eastern Time to discuss the financial results and provide a business update. The webcast will be accessible via a link on MannKind’s website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also ...

Core Insights - OPKO Health, Inc. reported business highlights and financial results for Q3 2025, including a collaboration with Regeneron Pharmaceuticals and the sale of BioReference Health assets [1][5]. Business Highlights - OPKO entered a research collaboration with Regeneron to develop multispecific antibodies, potentially exceeding $1 billion in value if multiple products succeed, with an upfront payment and milestone payments exceeding $200 million for each program [1]. - The sale of BioReference oncology assets to Labcorp for $225 million, including $192.5 million at closing and up to $32.5 million in performance-based earnout, aims to streamline operations and enhance profitability [1]. - Merck advanced the Phase 1 trial of an Epstein-Barr virus vaccine, with enrollment progressing well [1]. - The first patient was dosed in the MDX2004 Phase 1/2a study for advanced cancers, with data to be presented at the SITC annual meeting [1]. - Abstracts for various drug candidates, including MDX-2001 and OPK-88006, were presented at major medical conferences, indicating ongoing development in immunotherapy and metabolic disorder treatments [1]. Financial Results - Total revenues for Q3 2025 were $151.7 million, down from $173.6 million in Q3 2024, while operating income increased to $48.1 million from $14.2 million [5][13]. - Net income for Q3 2025 was $21.6 million, or $0.03 per diluted share, compared to $24.9 million, or $0.03 per diluted share, in the prior year [5][14]. - Revenue from products was $37.7 million, a slight decrease from $39.1 million in Q3 2024, while revenue from services dropped to $95.2 million from $121.3 million [5][13]. - Total costs and expenses decreased to $80.6 million in Q3 2025 from $84.6 million in the prior year, primarily due to lower sales volume and reduced employee-related expenses [5][13]. Cash Position - As of September 30, 2025, cash, cash equivalents, and restricted cash totaled $428.9 million, with $173.3 million received from the Labcorp transaction [5][11]. - Approximately $73.8 million of OPKO's common stock had been repurchased under the buyback program, with $126.2 million remaining authorized for future repurchases [5].

Core Insights - Revolution Medicines, Inc. is set to report its financial results for Q3 2025 on November 5, 2025, after market close [1] - A webcast will be hosted by the senior management team at 4:30 p.m. ET to discuss the financial results and corporate progress [1] Company Overview - Revolution Medicines is a late-stage clinical oncology company focused on developing targeted therapies for RAS-addicted cancers [3] - The company's R&D pipeline includes RAS(ON) inhibitors such as daraxonrasib (RMC-6236), elironrasib (RMC-6291), and zoldonrasib (RMC-9805), which are currently in clinical development [3] - The company plans to advance RMC-5127, a RAS(ON) G12V-selective inhibitor, into clinical development next [3] - Additional pipeline opportunities include RAS(ON) mutant-selective inhibitors like RMC-0708 (Q61H) and RMC-8839 (G13C) [3]

Core Insights - Tenable Holdings, Inc. reported better-than-expected financial results for Q3 2025, driven by strong demand for its Tenable One Exposure Management platform, reflecting a shift in the cybersecurity industry towards proactive risk management [2][6][7]. Financial Highlights - Revenue for Q3 2025 was $252.4 million, representing an 11% year-over-year growth [6][7]. - Calculated current billings reached $267.5 million, an 8% increase year-over-year [6][7]. - GAAP operating margin improved to 2.8%, compared to a loss of 0.9% in Q3 2024 [6][7]. - Non-GAAP operating margin increased to 23.3%, up 350 basis points year-over-year [6][7]. - GAAP net income was $2.3 million, a significant recovery from a loss of $9.2 million in Q3 2024 [6][7]. - Non-GAAP net income was $51.4 million, compared to $39.3 million in the same quarter last year [6][7]. Business Developments - The company added 437 new enterprise platform customers and 38 new six-figure customers during the quarter [6][7]. - Tenable launched Tenable AI Exposure, a solution aimed at managing risks associated with generative AI [6][7]. - The company was recognized as a "Leader" in Worldwide Exposure Management by IDC and Unified Vulnerability Management by Forrester [6][7]. Financial Outlook - For Q4 2025, Tenable expects revenue in the range of $249.1 million to $253.1 million [11]. - For the full year ending December 31, 2025, revenue is projected to be between $988.0 million and $992.0 million [11].

Company’s first metered-dose inhalation (MDI) product and establishes a new growth vector for the Affordable Medicines segmentBRIDGEWATER, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has tentatively approved the Company’s Abbreviated New Drug Application (ANDA) for beclomethasone dipropionate HFA inhalation aerosol (40 mcg/actuation and 80 mcg/actuation). The product is the generic equivalen ...

Third Quarter Results Total revenues of $46.5 million, a 6% year-over-year improvementNet income of $3.8 million and diluted earnings per share of $1.37, compared to net income of $4.1 million and diluted earnings per share of $1.60 in the same quarter of 2024Adjusted EBITDA of $7.0 million, consistent with the same quarter of 2024 $25.3 million in cash and $7.4 million of total debt as of September 30, 2025 HOUSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- NCS Multistage Holdings, Inc. (Nasdaq: NCSM) (the “Compan ...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRES OR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Giga Metals Corp. (“Giga Metals” or the “Company”) (TSX-V: GIGA; OTCQB: GIGGF; FSE: BRR2) is pleased to announce that further to its news release dated October 15, 2025, the Company has closed the first tranche of its previously announced private placement of Critical Minerals Flow-Through Units and Non-Flow-Through Units and increased aggregate proceeds up to $1,525,00 ...

Core Insights - Absci, a clinical-stage biotech company, is set to report its third quarter 2025 business updates and financial results on November 12, 2025, after market close [1] - A conference call will follow the report, starting at 4:30 p.m. Eastern Time, to discuss business developments and outlook [2] Company Overview - Absci is focused on drug discovery using generative design to create biologics more efficiently [3] - The company utilizes its Integrated Drug Creation™ platform, which combines AI models with a synthetic biology data engine for rapid therapeutic design [3] - Absci's pipeline includes ABS-101, aimed at treating inflammatory bowel disease, and ABS-201, a novel treatment for androgenetic alopecia [3] - The company operates from Vancouver, WA, with additional facilities in New York City and Switzerland [3]

Core Insights - Medallion Bank reported a net income of $19.8 million for Q3 2025, an increase from $15.5 million in the same quarter last year, driven by growth in recreation loans and stable performance in home improvement loans [3][6] - The bank's total loan portfolio was $2.3 billion as of September 30, 2025, down from $2.4 billion a year earlier, with recreation loans making up 66% of the total [6][7] - Strategic partnership loan originations reached a record $208 million in the quarter, indicating strong demand for consumer loans [3] Financial Performance - Net interest income increased to $55.9 million from $53.2 million year-over-year, with a net interest margin of 8.64%, up from 8.44% [6] - Total non-interest income rose to $2.3 million compared to $0.6 million in the prior year quarter [6] - The provision for credit losses decreased to $17.2 million from $20.2 million in the prior year quarter, reflecting improved asset quality [6] Loan Segments - The recreation loan portfolio was $1.546 billion as of September 30, 2025, with loan originations of $141.7 million, slightly up from $139.1 million in the prior year quarter [7] - Home improvement loan portfolio size was $804.0 million, down from $814.1 million a year earlier, with loan originations of $59.7 million [5][14] - Delinquencies for recreation loans increased to 4.97% from 4.15% year-over-year, while home improvement loans saw a decrease in delinquencies to 0.92% from 1.02% [7][14] Capital and Dividends - The bank's Tier 1 leverage ratio was 17.5% as of September 30, 2025, indicating strong capital position [6] - A quarterly cash dividend of $0.5625 per share on Series G preferred stock was declared, payable on January 2, 2026 [9]

Core Insights - Landmark Bancorp, Inc. reported a solid financial performance for the third quarter of 2025, with diluted earnings per share increasing to $0.85 from $0.75 in the previous quarter and $0.68 in the same quarter last year [1][4][24] - The company achieved net earnings of $4.9 million for the third quarter, up from $4.4 million in the prior quarter and $3.9 million in the same quarter of 2024, driven by growth in net interest income and non-interest income [1][4][24] Financial Performance - For the first nine months of 2025, diluted earnings per share reached $2.41, compared to $1.69 during the same period in 2024, with net earnings totaling $14.0 million, a 44.4% increase from $9.7 million in the first nine months of 2024 [2] - The return on average assets for the third quarter was 1.21%, and the return on average equity was 13.00%, reflecting improved profitability [1][6][27] Income and Expenses - Net interest income for the third quarter totaled $14.1 million, an increase of $411,000 or 3.0% from the previous quarter, and up $2.5 million or 21.5% from the same quarter last year [7][24] - Non-interest income increased to $4.1 million, a rise of $442,000 from the previous quarter, primarily due to gains on sales of residential mortgage loans and fees and service charges [8][24] - Non-interest expenses totaled $11.3 million, an increase of $290,000 or 2.6% compared to the prior quarter, driven by higher professional fees and occupancy expenses [9][24] Asset Quality - Non-performing loans decreased by $7.0 million to $10.0 million, representing 0.89% of gross loans, compared to 1.52% in the previous quarter [16] - The allowance for credit losses was $12.3 million, or 1.10% of total gross loans, down from $13.8 million or 1.23% in the prior quarter [15] Balance Sheet Highlights - As of September 30, 2025, total assets were $1.617 billion, with gross loans totaling $1.1 billion, largely consistent with the prior quarter [11][22] - Period-end deposit balances increased by $51.6 million to $1.3 billion, driven by increases in various deposit categories [12][22] - Stockholders' equity rose to $155.7 million, with a book value per share of $26.92, up from $24.18 a year earlier [13][14] Dividends - The Board of Directors declared a cash dividend of $0.21 per share, to be paid on November 26, 2025, and a 5% stock dividend payable on December 15, 2025, marking the 25th consecutive year of such dividends [4]